Article info.

ABSTRACT

Received 04 Mar 2020
Revised 23 Apr 2020

Accepted 31 Jul 2020

Belinostat, a histone deacetylases inhibitor, was reached the marketing approval by FDA for the treatment of relapsed and refractory peripheral T-cell lymphomas in 2014. Among 18 Histone Deacetylase (HDAC) enzymes, HDAC 8 has grabbed considerable attention from chemists as a promising target for cancer treatment, which leads to an ever-growing demand for the discovery of novel HDAC 8 inhibitors. With the advent of technologies, a useful and free-of-charge software – Autodock Tool was introduced to dock belinostat into the active site of HDAC 8 in this report. Nevertheless, docking to HDACs, known as metalloenzymes, still remains a challenge due to the interaction with Zn²⁺ ion at the bottom of the active binding site of the enzyme. For this reason, the extension of the Autodock forcefield to the new one named Autodock4Zn was utilized. The outcomes showed significant improvements in performance in both free energy of binding estimation as well as binding capacity of belinostat with different amino acids of HDAC8.

Keywords

Autodock4, Autodock4Zn, HDAC 8, metalloenzymes

Cited as: Thao, H.N., Toan, N.H., Si, N.T., Quoc, N.C., Quy, H.T.K., Bach, L.T., Tuan, N.T., Hue, B.T.B. and De, T.Q., 2020. Docking belinostat into HDAC 8 using autodock tool. Can Tho University Journal of Science. 12(2): 1-8.